October 30, 2006 (Las Vegas) — A medical approach consisting of 3 agents ("triple therapy") can reverse Barrett's esophagus and the dysplasia that often follows, eliminating the risk for esophageal ...

Traditionally, Barrett's esophagus was defined as the presence of columnar mucosa extending ≥ 3 cm into the tubular esophagus. This definition has evolved into the presence of any specialized columnar ...

A study published in the American Journal of Gastroenterology claims Barrett’s esophagus is unlikely to recur after treated with endoscopic eradication therapy coupled with effective reflux control.

The results of a new study appear to show that the use of aspirin can help reduce the risk of Barrett’s esophagus, according to a news release. The study was published in Clinical Gastroenterology and ...

A team led by researchers at Baylor College of Medicine and Washington University School of Medicine has shed light on the process that drives Barrett’s esophagus formation. This condition affects the ...

Castle Biosciences will present TissueCypher Barrett’s Esophagus test data at DDW 2025, emphasizing risk stratification and personalized patient management. Castle Biosciences, Inc. will present new ...

Endoscopies could be replaced by far less invasive capsule sponge tests for half of all patients with Barrett's esophagus, a known precursor to esophageal cancer, according to a new study from ...

Bethesda, MD (Oct. 17, 2025) — The American Gastroenterological Association (AGA) today released a new clinical practice guideline on the surveillance of Barrett's esophagus, the only known precursor ...

With this approval, all of the tests in Castle’s dermatology, gastroenterology and ophthalmology portfolios, as well as its clinical laboratories in Phoenix and Pittsburgh, are now approved by the ...

Thomas Jefferson University Hospital in Philadelphia has announced it has opened a new Barrett’s esophagus treatment center, according to a news release. The Jefferson Barrett’s Esophagus Treatment ...

TissueCypher is Castle’s precision medicine risk-stratification test that predicts a patient’s individual risk of progression from Barrett’s esophagus (BE) to esophageal cancer FRIENDSWOOD, ...